Introduction
Metastasis remains the most lethal aspect of cancer, yet identifying patients with systemic disease who will develop metastatic progression remains a challenge (1) .
Successful metastatic progression from disseminating tumor cells likely involves a combination of tumor-intrinsic characteristics and extrinsic signals from the local milieu of the distant site, much like stem cells within their specialized microenvironment, or niche (2) (3) (4) . Microenvironmental signals impact disseminating tumor cells and regulate quiescence or proliferation, survival or apoptosis, and renewal or differentiation(5-7).
The cell fate decision of these seeding tumor cells dictates metastatic progression and ultimately drives clinical outcome.
Previously, we demonstrated that tumor-derived factors form a metastasisconducive microenvironment by activating resident stromal cells and recruiting bone marrow-derived VEGFR1 + progenitor cells (8) . This process, which we termed the "premetastatic niche", not only introduced non-neoplastic cells as key players in metastatic progression, but also conveyed that cancer is systemic, utilizing niche biology for its dispersion (9, 10) . Others have confirmed and expanded the concept of the pre-metastatic niche, enforcing its essential role in the metastatic process (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . However, the initiating events that lead to pre-metastatic niche formation remain unclear. Moreover, a marker for pre-metastatic niche initiation in patients could provide a useful new addition to current approaches to stratify patients based on metastatic risk.
Our data suggest mobilized HSPCs emerging from tumor-mediated activation of the bone marrow can be used to monitor the metastatic process. HSPC production and mobilization are elevated in cancer patients and murine models before detectable metastases and foster an immunosuppressive milieu within the pre-metastatic niche of distant tissue sites. This is the first study to directly track the developmental fate of HSPCs in tumor-bearing hosts to identify the origins of MDSC formation. HSPCs represent a powerful tool as a potential novel approach to direct therapies based upon reestablishing the balance of altered hematopoiesis.
Results

Hematopoietic stem cells expand in response to a growing primary tumor.
We first defined tumor growth rate and metastatic progression after orthotopic injection for two C57BL/6 syngeneic tumor cell lines: the E0771 breast carcinoma (BCA) and M3-9-M rhabdomyosarcoma cell lines (ERMS) (Supplementary Figure 1) . Primary tumors release tumor cells early during tumor development, but the majority of these cells die upon vascular arrest or extravasation into distant tissues (21, 22) . To detect low numbers of disseminated luciferase-expressing tumor cells, we utilized the In Vivo
Imaging System (IVIS). In both models we identified a period before overt metastasis when either no cells or single tumor cells were detected in distant tissues. We termed this period "metastatic tumor seeding" and determined that it occurred during formation of the pre-metastatic niche.
We investigated the bone marrow (BM) as a potential source of the key hematopoietic component of the pre-metastatic niche and as one of the earliest targets of tumor-secreted factors given its integral role in the stress response to inflammation. The LSK gate (Lineage
) was utilized to identify the total population of HSPCs within the bone marrow ( Figure 1A) . Notably, these LSK HSPCs expressed VEGFR1, a potential marker for this population that is consistent with our previous studies ( Figure   1B ) (8) . The total number of LSK HSPCs in the bone marrow of tumor-bearing E0771 BCA and M3-9-M ERMS mice significantly increased within the two weeks following tumor implantation and their numbers doubled, relative to basal levels, during the period of metastatic tumor seeding ( Figure 1C and D) . BrdU uptake analysis demonstrated a greater number of proliferating LSK cells in the bone marrow of pre-metastatic E0771 BCA tumor-bearing mice relative to controls ( Figure 1E ). Furthermore, a significantly greater proportion of the LSK population was proliferating in tumor-bearing relative to control mice (40% versus 19%, respectively; Figure 1F ).
LSK HSPCs can be sub-divided by flow cytometric analysis into Flt3 HSPCs are mobilized during pre-metastatic niche initiation and contribute to myeloid subsets in pre-metastatic sites.
Flow cytometry analysis of peripheral blood revealed significantly elevated numbers of LSK HSPCs during formation of the pre-metastatic niche in both the E0771 BCA and M3-9-M ERMS models (Figure 2A-2B ). Elevated levels of stem-like hematopoietic progenitor cells in the peripheral blood of pre-metastatic mice were confirmed functionally with a colony forming unit assay ( Figure 2C ). Together, these data demonstrate that LSK HSPCs expand and mobilize in response to a growing primary tumor. Because these events occurred during pre-/early metastatic period, we sought to determine if expanded LSK HSPCs in circulation contributed to hematopoietic cell types within the pre-metastatic site. oxygen species with inducible nitric oxide synthase (iNOS) (28) . To determine whether the MDSCs isolated from pre-metastatic lungs utilized these pathways to mediate T cell suppression, we performed a T cell suppression assay in the presence of the arginase inhibitor, NOR-NOHA, or the iNOS inhibitor, L-NMMA. MDSCs cultured with L-NMMA, but not NOR-NOHA, were significantly impaired in their ability to suppress T cell proliferation ( Figure 2K ). Therefore, MDSCs found within pre-metastatic or early metastatic sites are functionally capable of suppressing T cell proliferation, and the suppression is mediated in part by iNOS activity. 
Circulating HSPCs promote experimental metastasis.
We next sought to determine if mobilization of HSPCs could confer a survival advantage to disseminating tumor cells. To mimic the surge in circulating LSK HSPCs induced by a primary tumor, we targeted the CXCL12 pathway that tethers LSK within the bone marrow niche. This pathway was targeted due to our earlier finding that the CXCL12:CXCR4 axis was altered in the bone marrow of tumor-bearing mice (Supplementary Figure 2A) . We utilized the CXCR4 receptor antagonist AMD3100, which rapidly and acutely mobilizes CXCR4-expressing hematopoietic cells by transiently blocking the CXCR4:CXCL12 axis when administered in a single dose (30, 31) . Importantly, AMD3100, similar to G-CSF, mobilizes HSPCs but does not promote myeloid lineage skewing as seen with G-CSF. and an overall increase in metastatic progression. Prior to injection, E0771 BCA cells were assessed for CXCR4 receptor expression by flow cytometry, and it was found to be absent, indicating that AMD3100 was working through a direct effect on HSPC mobilization (Supplementary Figure 2E) .
Since we determined that circulating HSPCs differentiated into myeloid cells in the pre-metastatic site, we hypothesized that immune evasion may provide one mechanism by which HSPCs promoted metastasis. Loss of radiosensitive hematopoietic cells completely abrogated the metastasis-promoting effects of AMD3100 pre-treatment, further implicating this population in metastatic progression ( Figure 5A ). In addition, mobilization of LSK HSPCs by AMD3100 had no effect on metastatic burden or survival in immunodeficient SCID/Beige mice, demonstrating that the enhanced metastatic effect of AMD3100 is not tumor-intrinsic but due to T cell-dependent immune suppression ( Figure 5B ). Finally, to specifically assess the functional role of LSK HSPC differentiation into myeloid cells during metastatic progression, we utilized a monoclonal anti-Gr-1 antibody to specifically target Gr-1-expressing myeloid cells. The metastasispromoting effect of AMD3100 treatment was completely abrogated with anti-Gr-1 treatment ( Figure 5C-5F ). Together, these data suggest a model whereby mobilized LSK HSPCs provide an upstream component to the immune suppressive microenvironment and contribute to immune suppressive myeloid populations within pre/early metastatic sites.
Mobilized HSPCs as a marker of metastatic progression.
We next sought to determine if mobilized HSPCs observed in our murine models could translate to clinical samples. Consistent with our murine studies, blood from patients with rhabdomyosarcoma or early stage breast cancer displayed significantly enhanced granulocytic/monocytic CFU potential, demonstrating that circulating HSPCs were present in patients with cancer ( Figure 6A and 6B). We further sought to evaluate whether the level of circulating HSPCs marked by VEGFR1 and CD34, an established marker for human hematopoietic stem and progenitor cells, were associated with risk of metastatic disease in patients with cancer. In rhabdomyosarcoma patients stratified by standard risk assessment, those patients with the highest risk of metastasis had the highest levels of circulating VEGFR1 on molecular subtype, and these subtypes show differential risk of metastatic disease, disease recurrence, as well as clinical outcome and risk for death due to disease (32) .
Patients with all subtypes of invasive breast carcinoma had increased circulating HSPCs at diagnosis relative to patients with non-metastatic, non-invasive ductal carcinoma in situ (DCIS) ( Figure 6D ). These findings are supported by recent work in xenograft breast cancer dormancy models (9). Intriguingly, the highest level of circulating HSPCs relative to DCIS and those patients with luminal A subtype were seen in patients with the triple negative molecular subtype, which is associated with a higher risk for disease progression (P<0.005).
To determine if circulating HSPCs could predict metastatic relapse, we prospectively measured circulating HSPC levels in newly diagnosed rhabdomyosarcoma patients. The patients who proceeded to develop metastatic progression had significantly greater levels of circulating HSPCs at time of diagnosis than patients who did not relapse.
This suggests that this marker, if validated in larger cohorts, could predict at the time of diagnosis which patients are most likely to develop relapsed metastatic disease, even within an intermediate or high risk subpopulation ( Figure 6E ). Together, these data suggest that circulating HSPCs in both murine models and cancer patients can contribute to the metastatic process and may be used to identify populations at great risk for metastatic relapse.
Discussion
The bone marrow responds to cues from distant tissues during stresses such as infection, inflammation, and wound healing and induces hematopoietic stem cells to reversibly exit quiescence, expand, and enter circulation (33) (34) (35) . During a wound- RayBio Cytokine Array: E0771 and M3-9-M were grown in RPMI 1640 with 1% fetal calf serum and 1% penicillin/streptomycin overnight. Tumor-conditioned media were centrifuged and passed through a 0.22µm filter prior to use in the array. RayBio C1000 array was used to detect tumor-secreted cytokines.
Ex vivo bone marrow culture: Lineage-depleted bone marrow was collected using the EasySep mouse hematopoietic progenitor cell enrichment kit. Cells were cultured for 7 days in StemSpan serum-free expansion medium with 25ng/mL recombinant murine CAN-15-0204 1mM EDTA. Lungs were perfused with normal saline to remove peripheral blood and minced with a scalpel. Lung pieces were digested in DMEM with 1mg/mL type I collagenase at 37C for 30 minutes with gentle agitation. Lung fragments were dissociated by pressing against a 70µm nylon filter. Whole bone was crushed in Trizol using a homogenizer at 40s intervals. Total RNA was isolated and precipitated from Trizol using chloroform/ethanol extraction, and further purified and DNase I treated using the Qiagen Micro RNA Isolation kit. RNA concentration and quality was assessed by an Agilent 2100 Bioanalyzer.
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Primer Sequences
Primer Sequence
CXCL12-F TGCATCAGTGACGGTAAACCA CXCL12-R TTCTTCAGCCGTGCAACAATC B-actin-F GGCTGTATTCCCCTCCATCG B-actin-R CCAGTTGGTAACAATGCCATGT Quantitative Real-Time PCR: cDNA synthesis was performed on 1ug RNA per sample using the BioRad iScript cDNA synthesis kit and qRT-PCR was performed using the BioRad SsoAdvanced system and iCycler technology. E-F. Survival of mice administered isotype antibody followed by AMD3100 or PBS (E) and mice administered anti-Gr-1 antibody followed by AMD3100 or PBS (F). 
